Tenax's TNX-103 misses primary endpoint in Phase 3 LEVEL trial for PH-HFpEF
Subgroup analyses showed benefit in sicker patients, and the company plans to seek an FDA meeting to discuss adjusting the registrational program.
SEC filing
Latest
2 stories
Monday, August 10
Friday, July 31
Tenax reports Q2 2026 results, confirms August LEVEL trial data and ESC presentation
Tenax says topline Phase 3 LEVEL results are expected in August 2026 and will be presented at the ESC Congress, while enrollment continues in a second pivotal trial, LEVEL-2.
SEC filing